| Abstract | Breast cancer in males is uncommon, occurring at approxiamtely 1% of the rate of female breast cancer. Male breast carcinomas tend to be highly positive for hormone receptors, including oestrogen, progesterone and androgen receptors. Owing to this, hormone therapy is recommended as the primary treatment modality. Adjuvant therapy is recommended for male breast cancers with large size or positive axillary nodes. For metastatic disease, options for therapy include tamoxifen, orchiectomy, anti-androgens with or without luteinising hormone releasing hormone analogues or combination chemotherapy. The newer hormonal treatments, such as the selective aromatase inhibitors or novel antioestrogens, have not yet been well studied in male breast cancer but have potential for efficacy in this disease. |
| Authors | Teresa Hayes
(Affiliation: Baylor College of Medicine, Houston, Texas, USA. thayes at bcm.tmc.edu)
|
| Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 3
Issue 6
Pg. 701-8
(Jun 2002)
ISSN: 1465-6566 England |
| PMID | 12036409
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review)
|
| Chemical References |
- Androgen Antagonists
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Receptors, Estrogen
|
| Topics |
- Androgen Antagonists
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Aromatase Inhibitors
- Breast Neoplasms, Male
(drug therapy, genetics, pathology)
- Chemotherapy, Adjuvant
- Humans
- Male
- Neoplasm Metastasis
- Receptors, Estrogen
(drug effects)
- Risk Factors
|
